Oryzon Genomics SA (ORYZF)
3.36
0.00 (0.00%)
USD |
OTCM |
Aug 24, 16:00
Oryzon Genomics Enterprise Value : 250.36M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 250.36M |
| August 21, 2026 | 250.36M |
| August 20, 2026 | 250.36M |
| August 19, 2026 | 250.36M |
| August 18, 2026 | 250.36M |
| August 17, 2026 | 250.36M |
| August 14, 2026 | 250.36M |
| August 13, 2026 | 251.13M |
| August 12, 2026 | 251.13M |
| August 11, 2026 | 251.13M |
| August 10, 2026 | 261.21M |
| August 07, 2026 | 261.21M |
| August 06, 2026 | 261.21M |
| August 05, 2026 | 261.21M |
| August 04, 2026 | 261.21M |
| August 03, 2026 | 261.21M |
| July 31, 2026 | 261.21M |
| July 30, 2026 | 257.33M |
| July 29, 2026 | 257.33M |
| July 28, 2026 | 257.33M |
| July 27, 2026 | 257.33M |
| July 24, 2026 | 273.23M |
| July 23, 2026 | 273.23M |
| July 22, 2026 | 273.23M |
| July 21, 2026 | 273.23M |
| Date | Value |
|---|---|
| July 20, 2026 | 273.23M |
| July 17, 2026 | 273.23M |
| July 16, 2026 | 273.23M |
| July 15, 2026 | 273.23M |
| July 14, 2026 | 273.23M |
| July 13, 2026 | 273.23M |
| July 10, 2026 | 273.23M |
| July 09, 2026 | 273.23M |
| July 08, 2026 | 273.23M |
| July 07, 2026 | 273.23M |
| July 06, 2026 | 273.23M |
| July 02, 2026 | 273.23M |
| July 01, 2026 | 273.23M |
| June 30, 2026 | 273.23M |
| June 29, 2026 | 266.01M |
| June 26, 2026 | 265.23M |
| June 25, 2026 | 265.23M |
| June 24, 2026 | 265.23M |
| June 23, 2026 | 265.23M |
| June 22, 2026 | 265.23M |
| June 18, 2026 | 265.23M |
| June 17, 2026 | 265.23M |
| June 16, 2026 | 265.23M |
| June 15, 2026 | 265.23M |
| June 12, 2026 | 265.23M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pharma Mar SA | 1.378B |
| Grifols SA | 14.00B |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alkermes Plc | 9.104B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.1678M |
| Total Expenses (Quarterly) | 0.1678M |
| EPS Diluted (Quarterly) | -0.0022 |
| Earnings Yield | -1.06% |
| Normalized Earnings Yield | -1.060 |